Profound Medical prelim Q3 2026 revenue $9.8-10.0M, up ~85-89% YoY and 45-47% above consensus

Profound Medical Corp.

Preliminary Q3 2026 total revenue expected at $9.8M-$10.0M, versus Bloomberg mean analyst consensus of $6.78M as of Oct 7, 2026.
Revenue up approximately 85% to 89% YoY from $5.3M in Q3 2025, and up 292% to 300% sequentially from $2.5M in Q2 2026.
Q3 2026 gross margin expected to again exceed 70%, which the company attributes to commercial operations and scale.
CEO Arun Menawat cites increased commercial activity across the installed base and new customer accounts; figures are preliminary and unaudited.
Full Q3 2026 results due after market close Thursday, November 5, 2026, with a conference call at 4:30 p.m. ET.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.